Serum Galectin-3 as a Marker of Human Papillomavirus Infection

Assiut University

Status: Completed

Conditions: Human Papillomavirus Infection

Treatments: Diagnostic Test: serum Galectin-3 assay; Procedure: cryotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06005389

Galectin-3 and HPV infection

Details and patient eligibility

About

This study aimed to assess the serum Galectin-3 levels in patients with warts both before and after cryotherapy and to investigate its potential contribution to the pathogenesis of human papillomavirus infection.

Full description

Galectin-3 regulates many functions at the cellular level such as cell attachment, proliferation, and apoptosis. Numerous viral illnesses, including human papillomavirus infection, were reported to have elevated serum levels of Galectin-3. .

Methods: Fifty patients suffering from warts, and fifty healthy controls were included in this study. Enzyme-linked immunosorbent assay was used to measure serum levels of Galectin-3 both before and 2 weeks after the last cryotherapy session.

Enrollment: 100 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients with non-genital warts.
2. Age of patients: from 18 to 60 years.

Exclusion criteria

1. Patients with genital and mucosal warts.
2. Pregnancy and breastfeeding.
3. Patients who received any wart treatment during the last month before enrollment in the study.

Trial design

100 participants in 2 patient groups

50 patients with common or planter cutaneous warts

Description:

Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. The therapeutic efficacy was evaluated by a decrease in the size (measured by a ruler) and the number of warts with photographic documentation at (the baseline, each visit, 2 weeks after the final session, and the 3 months follow-up period). The response of the treated wart was considered: complete; if there was a disappearance of the wart and appearance of normal skin markings, partial; if the warts had regressed in size or decreased in number and no response; if no decrease in wart size or number. From each patient 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits.

Treatment:

Diagnostic Test: serum Galectin-3 assay

Procedure: cryotherapy

50 healthy age-and sex-matched control subjects.

Description:

From each control subject, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits.

Treatment:

Diagnostic Test: serum Galectin-3 assay